Dr. Sonja Karst
Head of the DRRG Vienna
Univ. Prof. Dr. Christoph Scholda
Head of the diabetes outpatient clinic
Dr. Christoph Mitsch
Assoz.-Prof.in Priv.-Doz.in Dr.in Katharina Kriechbaum
Dr.in Julia Hafner
Location: Department of Ophthalmology, Floor 8i
Phone (appointments): +43 (1) 40400 - 60000
The aim of the DRRG Vienna is to gain further insight into patho-morphological and patho-physiological retinal changes secondary to diabetes mellitus. Actual and novel ophthalmological treatment modalities and their effects on retinal function and morphology are analyzed in prospective clinical trials. Together with our patients, partners of the scientific community and the industry we investigate new diagnostic and therapeutic tools always aiming for improvement and pharmacological and technological progress.
The purpose of these analyses is to improve therapeutic options helping to prevent sight deterioration or visual impairment secondary to diabetes mellitus. Therefore we also participate in multi-center clinical trials evaluating novel therapeutic strategies.
OCT angiography, Swept source OCT, spectral domain OCT, polarization-sensitive OCT, adaptive optics OCT, adaptive optics SLO, confocal cornea microscopy, ultra-wide field imaging, fluorescence angiography, pattern laser, micropulse laser
PONTIAC 2 Eye-Study (recruiting)
Impact of high dose β-¬‐Blocker and ACE Inhibition on early retinal changes in diabetic patients. In cooperation with the Department of Cardiology, we investigate preclinical changes of the neurosensory retina and the supplying capillary network to find new biomarkers of disease progression.
Ophthalmic neurodegeneration in type II Diabetes (recruiting)
The purpose of this study is to compare the severity and define the correlation between retinal and corneal neurodegeneration in type II diabetic patients according to the presence and stage of diabetic retinopathy.
AQUA Trial (follow up)
Open-label Phase-4 study to examine the change of vision-related quality of life in subjects with diabetic macular edema (DME) during treatment with intravitreal injections of 2 mg aflibercept according to EU label for the first year of treatment
Aflibercept in diabetic macular edema (recruiting)
Thorough investigation of functional and morphologic changes in patients with DME following intravitreal treatment with aflibercept.
Aflibercept in proliferativ diabetic retinopathy (coming soon)
Clinical trial investigating morphologic changes of the retina and its capillary network following intravitreal treatment with aflibercept.
Visual quality in diabetic patients (recruiting)
The visual quality of diabetic subjects is compared to an age-matched cohort reflecting the general population.
In case you are interested to participate in one of our clinical trials, we kindly ask you to get a letter of referral from your ophthalmologist addressed to our outpatient clinic at the Department of Ophthalmology, level 8i, General Hospital Vienna. We will be happy to inform you about your benefits and your possible risks of participation in one of our clinical trials.
Please don’t hesitate to contact us: +43 1 40400 60000